HBM Healthcare Investments top holding AAA receives takeover bid from Novartis
Tender offer for 100% of radiotherapeutic oncology specialist Advanced Accelerator Applications at 25% premium to 30 September valuation
Switzerland-based global healthcare giant Novartis has announced a takeover bid for Advanced Accelerator Applications (AAA), the largest holding of specialist investment fund HBM Healthcare Investments (HBMN). The deal values AAA, whose Lutathera treatment for neuroendocrine tumours was granted EU approval in September 2017, at US$3.9bn.
HBMN, which holds both listed and unlisted investments in its global portfolio of healthcare companies and funds, first invested in AAA in February 2014 when it was still a private company. The fund is AAA’s second-largest shareholder, with 2.4m American Depositary Shares (ADS) (down from a peak of 3.5m) representing 7.0% of the company. At HBMN’s 30 September 2017 half-year end, the shares were valued at CHF157.1m; the US$41 per ordinary share/$82 per ADS tender price (at current exchange rates) increases the value of the stake to CHF196.5m, a 25% uplift.
AAA has signed a memorandum of understanding with Novartis, which will proceed with the cash tender offer subject to AAA’s directors recommending the deal to shareholders, and a satisfactory works council consultation.
If the tender is successful, the proceeds of the takeover will increase HBMN’s NAV per share by 2.5% (based on the last reported 15 October NAV). The tender price is more than 600% higher than the average US$11.66 HBMN paid to acquire the shares.
Read our latest research on HBMN here.
Disclaimer - Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. This document may contain materials from third parties, which are supplied by companies that are not affiliated with Edison Investment Research. Edison Investment Research has not been involved in the preparation, adoption or editing of such third-party materials and does not explicitly or implicitly endorse or approve such content. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of publication and is subject to change without notice. While based on sources believed reliable, we do not represent this material as accurate or complete. Any views or opinions expressed may not reflect those of the firm as a whole. Edison Investment Research does not engage in investment banking, market making or asset management activities of any securities. The material has not been prepared in accordance with the legal requirements designed to promote the independence or objectivity of investment research.